| |
Market and value analysis positions neurotech startup for successful U.S. product commercialization and adoption. Learn how. .png)
|
|
Today's Big NewsJun 23, 2023 |
| By Nick Paul Taylor Roche has bowed out of the race to develop an antisense oligonucleotide (ASO) for Angelman syndrome. After getting a look at early efficacy data, the Swiss drugmaker opted against advancing the candidate, switching its Angelman focus to another asset and leaving the ASO space to Biogen, Ionis and Ultragenyx. |
|
|
|
| July 18-19, 2023 | Jersey City, NJ |  |
|
|
By Angus Liu Even after a second application attempt, Intercept’s Ocaliva wasn’t the fatty liver disease breakthrough that the company had hoped it would be. Intercept is now swinging into restructuring mode, and the NASH baton passes on to Madrigal Pharma. |
By James Waldron Barely six months after launching, Paragon Therapeutics’ first spinout has set its sights on the public markets as well as taking on some of the biggest names in immunology and inflammation. |
By Andrea Park The next year is set to be a busy one for Allurion: Not only is the weight-loss technology maker planning to go public this summer, but it has also now tapped Medtronic to help bring its technology to even more healthcare providers and patients around the world. |
|
Wednesday, July 12, 2023 | 2pm ET / 11am PT In this webinar, we will explore how critical it is for life sciences companies to use data to analyze the behavior of cancer at the individual level, uncover new targets and biomarkers for precision therapies, and increase the value of existing oncology drugs to new indications. Register now. 
|
|
By Zoey Becker GSK can now wipe an upcoming California Zantac trial off its plate with a confidential settlement a month before what would have been the first state-level trial. |
By James Waldron Laying off “substantially all” your workforce is normally a sign that a biotech is in a death spiral, but Acasti Pharma’s CEO is insistent that the move has “energized” the company as it gears up for a phase 3 study of its lead asset. |
By Kevin Dunleavy After years of using the patent system to delay competition to its key Xyrem/Xywav franchise from a rival company, Jazz Pharmaceuticals is taking a new route—suing the FDA. |
By Max Bayer,Gabrielle Masson When Bayer named former Roche pharma chief Bill Anderson as its new CEO, it was clear the company would be leaning into its pharmaceutical business focus moving forward. That’s been further cemented with the promotion of Sebastian Guth as head of the company’s U.S. operations. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the most expensive drugs in the U.S., plus Eli Lilly's recent acquisition, the latest company to challenge the Inflation Reduction Act, and the rest of the week's headlines. |
|
|---|
|
|
|
Wednesday, July 12, 2023 | 11am ET / 8am PT Join us for this insightful discussion on how to unlock the full potential of liquid biopsy and be an integral part of the future of precision medicine. We’ll take a deep dive into the latest strategies and solutions designed to help overcome current challenges and empower researchers and clinicians with enhanced capabilities. Register now. 
|
|
Whitepaper Learn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
